New application of peroxidase acyl coenzyme A oxidase 1

An enzyme acyl-coenzyme, peroxide technology, applied in the new application field of peroxidase acyl-CoA oxidase 1, can solve the problem that the preventive effect is less than 100%, there is no EV71 infection, and the vaccine cannot be used to treat EV71 infection, etc. question

Active Publication Date: 2020-08-18
广东龙帆生物科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Through the above analysis, the problems and defects of the prior art are: (1) there is no relevant report about the antiviral effect of peroxisome and ACOX1 on EV71
[0008] (2) Currently there is no effective antiviral drug to treat severe EV71 infection;
[0009] (3) The vaccine can only prevent but not treat EV71 infection, and the preventive effect cannot reach 100%.
[0010] The difficulty of solving the above problems and defects is: the development of antiviral drugs is a time-consuming and costly work. Although many pharmaceutical companies and research institutions have carried out research and development work for many years, so far there is no new anti-EV71 drug on the market.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of peroxidase acyl coenzyme A oxidase 1
  • New application of peroxidase acyl coenzyme A oxidase 1
  • New application of peroxidase acyl coenzyme A oxidase 1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0035] In order to make the object, technical solution and advantages of the present invention more clear, the present invention will be further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0036] Aiming at the problems existing in the prior art, the present invention provides a new application of peroxidase acyl-CoA oxidase 1. The present invention will be described in detail below with reference to the accompanying drawings.

[0037] The invention provides the use of peroxidase acyl-CoA oxidase 1 in the preparation of medicines for treating or preventing enterovirus infection.

[0038] The peroxidase acyl-CoA oxidase 1 protein dose concentration was 13.5 ng / ml or 337.5 ng / ml.

[0039] Preferably 13.5 ng / ml.

[0040] The present invention provides a pharmaceutically acceptable dosage form prepared by using ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of antiviral drugs and discloses new application of peroxidase acyl coenzyme A oxidase 1. Firstly, an insect baculovirus expression vector system is used for expressing ACOX1 protein in an insect cell SF9, then a nickel column affinity chromatography method is used for purifying the ACOX1 protein, and finally the antiviral effect of the ACOX1 protein isverified in malignant embryo rhabdomyoma cells RD infected with EV71. Experimental results prove that the purified ACOX1 protein can inhibit EV71 virus replication at the mRNA level and the protein level at a certain concentration. According to the invention, the anti-EV71 virus effect of peroxidase acyl-CoA oxidase 1 (ACOX1) is evaluated from cell and molecular levels, and a good foundation is laid for further development and application. It is shown that the medicine has the prospect of being developed into an effective medicine for resisting EV71 viruses to be applied in clinic.

Description

technical field [0001] The invention belongs to the technical field of antiviral drugs, and in particular relates to a new application of peroxidase acyl-CoA oxidase 1. Background technique [0002] Currently, Human enterovirus 71 (Human enterovirus, EV71) belongs to the genus Enterovirus of the Picomaradae family. The EV71 virus particle is an icosahedral symmetrical spherical structure without envelope and spikes, and its diameter is about 24–30nm. The full length of the viral genome is 7408bp, which is a single-stranded positive-sense RNA. There is only one open reading frame (ORF) in the genome, and there are 5' and 3' non-coding regions (UTRs) on both sides of the ORF, and at the end of the 3' end of the genome There is also a polyadenylic acid tail (poly-A) of variable length. The ORF in the viral genome can encode 2194 amino acids, and the polyprotein composed of these amino acids can produce a total of three precursor proteins, P1, P2 and P3. Among them, the P1 pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/44A61P31/14C12N15/866C12N15/62C12N9/02C12Q1/70C12Q1/02C12R1/93
CPCA61K38/44C12Y103/03006A61P31/14C12N15/86C12N9/001C12Q1/02C12N2710/14043C12N2800/105C07K2319/21G01N2333/085Y02A50/30
Inventor 吴建国游蕾邬开朗刘映乐谭秋萍
Owner 广东龙帆生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products